SMMT - NASDAQ
Summit Therapeutics Inc.
$15.07
+1.4%Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotSummit Therapeutics Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$161.5M | -$80.7M | -$40.4M | -$20.2M | -$10.1M | -$5.0M | -$2.5M | -$1.3M | -$630.7K | -$315.4K |
| Maintenance CapEx | -$65.7K | -$32.9K | -$16.4K | -$8.2K | -$4.1K | -$2.1K | -$1.0K | -$513 | -$257 | -$128 |
| Owner Earnings | -$161.5M | -$80.8M | -$40.4M | -$20.2M | -$10.1M | -$5.0M | -$2.5M | -$1.3M | -$631.0K | -$315.5K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$149.6M | -$69.2M | -$32.1M | -$14.8M | -$6.9M | -$3.2M | -$1.5M | -$681.8K | -$315.6K | -$146.1K |
Related Guides
Continue your SMMT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.